Euchrenone A10

Euchrenone A10 (A10), an isoprenylated flavanone isolated from Glycyrrhiza (licorice), exhibits significant bioactivities, including anti-inflammatory and antioxidant effects. However, the effects and mechanisms underlying A10's protective role in sepsis-associated acute lung injury (SALI) remain incompletely understood.

This study aims to elucidate the pharmacological effects of A10 and the underlying mechanisms by which it protects against SALI, using both in vitro and in vivo experiments.

To evaluate the effects of A10 against SALI, mice were pretreated with A10 (12.5, 25, or 50 mg/kg) or dexamethasone (Dex, 50 μg/kg) prior to sepsis induction via intraperitoneal administration of lipopolysaccharide (LPS, 10 mg/kg) or cecal ligation and puncture (CLP). Survival rates, pulmwasy function, bronchoalveolar lavage fluid inflammatory cell infiltration, protein exudation, and lung histopathology were systematically assessed. Molecular docking and biolayer interferometry (BLI) were employed to characterize the interactions between S100A8/A9 and A10 or paquinimod (paq). Complementary in vitro studies using LPS (150 ng/ml)-stimulated Raw264.7 macrophages were conducted to examine A10's effects on inflammatory gene expression.

To evaluate the therapeutic effects of A10, we employed LPS-induced SALI and CLP-induced ALI models. A10 dose-dependently alleviated pulmonary injury and improved survival rates in septic mice. Notably, A10 inhibited the expression of S100A8/A9 and suppressed the TLR4/MyD88/NF-κB signaling pathway in both in vivo and in vitro models. Mechanistic studies using molecular docking and BLI indicated that A10 directly binds to S100A8/A9, thereby blocking its interaction with the TLR4 receptor. Furthermore, in vivo and in vitro experiments confirmed that A10 shares the same binding site on S100A8/A9 as the S100A9-specific inhibitor paq, competitively displacing paq and inhibiting downstream TLR4/MyD88/NF-κB signaling.

A10 exerts its anti-inflammatory effects by binding to the S100A8/A9 protein, thereby inhibiting the TLR4-NF-κB inflammatory cascade. These properties highlight its therapeutic potential as monotherapy for SALI.